Therapy-related acute myeloid leukemia with inv(16) after treatment of Hodgkin lymphoma: report of one case and review of literature
10.3760/cma.j.issn.1009-9921.2018.02.011
- VernacularTitle:霍奇金淋巴瘤治疗后继发急性髓系白血病伴染色体核型inv(16)一例并文献复习
- Author:
Wenbin CAO
1
;
Jiali SUN
;
Lukun ZHOU
;
Xiaohui ZHENG
;
Shulian CHEN
;
Rongli ZHANG
;
Yi HE
;
Sizhou FENG
;
Donglin YANG
Author Information
1. 中国医学科学院 北京协和医学院血液学研究所 血液病医院造血干细胞移植中心
- Keywords:
Lymphoma,Hodgkin;
Leukemia;
Neoplasms;
second primary;
Hematopoietic stem cell transplantation
- From:
Journal of Leukemia & Lymphoma
2018;27(2):108-112
- CountryChina
- Language:Chinese
-
Abstract:
Objective To improve the recognition of therapy-related acute myeloid leukemia (t-AML). Methods One patient who was diagnosed as AML with inv (16) following treatment of Hodgkin lymphoma (HL) was reported. The pathomechanism, diagnosis, treatments and prognosis of t-AML were systematically studied by reviewing a series of literature. Results A 36-year-old female with a history of HL 2 years ago was diagnosed t-AML. Karyotype analysis demonstrated inv (16) and the fusion gene of CBFβ/MYH11 was positive by polymerase chain reaction (PCR). The fusion gene of CBFβ/MYH11 was still positive after receiving 3 courses of chemotherapy. The leukemia reached completely molecular biological remission after receiving haploidentical peripheral blood stem cell transplantation. The patient has now survived 1.5 years with leukemia free and in a good performance. Conclusions The t-AML is difficult to treat, but it is heterogeneous. Cytogenetics and molecular biology have important implications for the prognosis of t-AML. Currently, allogeneic hematopoietic stem cell transplantation is the only effective way to cure t-AML.
